Institution
Taipei Veterans General Hospital
Healthcare•Taipei, Taiwan•
About: Taipei Veterans General Hospital is a healthcare organization based out in Taipei, Taiwan. It is known for research contribution in the topics: Population & Cancer. The organization has 11878 authors who have published 16478 publications receiving 363424 citations. The organization is also known as: Táiběi Róngmín Zǒngyī Yuàn.
Topics: Population, Cancer, Medicine, Hazard ratio, Atrial fibrillation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is demonstrated that the EMT transcriptional factor Snail directly activates the transcription of MIR21 to produce miR-21-abundant tumor-derived exosomes (TEXs), which may serve as a candidate biomarker of tumor progression and provide a potential target for intercepting EMT-mediated TME remodeling.
120 citations
••
University of North Carolina at Chapel Hill1, University of Michigan2, National Yang-Ming University3, National Defense Medical Center4, Rutgers University5, University of Alabama at Birmingham6, University of Texas Health Science Center at Houston7, National Institutes of Health8, Fred Hutchinson Cancer Research Center9, University of Hawaii10, Vanderbilt University11, Brown University12, Cedars-Sinai Medical Center13, University of Southern California14, Norwegian University of Science and Technology15, University of Iowa16, University of Eastern Finland17, Washington University in St. Louis18, National Health Research Institutes19, University of Tromsø20, Baylor College of Medicine21, University of Washington22, Johns Hopkins University School of Medicine23, Translational Genomics Research Institute24, University of San Carlos25, Taipei Veterans General Hospital26, University of Utah27, National Taiwan University28, Oulu University Hospital29, Stanford University30
TL;DR: The authors conducted a trans-ethnic fine-mapping study at 18, 22, and 18 GWAS loci on the Metabochip for their association with triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density LDL-C, respectively, in individuals of African American, East Asian, and European ancestry.
Abstract: Genome-wide association studies (GWAS) have identified ~100 loci associated with blood lipid levels, but much of the trait heritability remains unexplained, and at most loci the identities of the trait-influencing variants remain unknown. We conducted a trans-ethnic fine-mapping study at 18, 22, and 18 GWAS loci on the Metabochip for their association with triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), respectively, in individuals of African American (n = 6,832), East Asian (n = 9,449), and European (n = 10,829) ancestry. We aimed to identify the variants with strongest association at each locus, identify additional and population-specific signals, refine association signals, and assess the relative significance of previously described functional variants. Among the 58 loci, 33 exhibited evidence of association at P<1 × 10(-4) in at least one ancestry group. Sequential conditional analyses revealed that ten, nine, and four loci in African Americans, Europeans, and East Asians, respectively, exhibited two or more signals. At these loci, accounting for all signals led to a 1.3- to 1.8-fold increase in the explained phenotypic variance compared to the strongest signals. Distinct signals across ancestry groups were identified at PCSK9 and APOA5. Trans-ethnic analyses narrowed the signals to smaller sets of variants at GCKR, PPP1R3B, ABO, LCAT, and ABCA1. Of 27 variants reported previously to have functional effects, 74% exhibited the strongest association at the respective signal. In conclusion, trans-ethnic high-density genotyping and analysis confirm the presence of allelic heterogeneity, allow the identification of population-specific variants, and limit the number of candidate SNPs for functional studies.
119 citations
••
TL;DR: This manuscript summarizes the international consensus statements developed at APPLE 2019 and says that TACE should not be continued in patients who develop TACE failure/refractoriness in order to preserve liver function.
Abstract: The Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement on the treatment strategy for patients with intermediate-stage hepatocellular carcinoma (HCC) was established on August 31, 2019, in Sapporo, Hokkaido during the 10th Annual APPLE Meeting. This manuscript summarizes the international consensus statements developed at APPLE 2019. Transarterial chemoembolization (TACE) is the only guideline-recommended global standard of care for intermediate-stage HCC. However, not all patients benefit from TACE because intermediate-stage HCC is a heterogeneous disease in terms of tumor burden and liver function. Ten important clinical questions regarding this stage of HCC were raised, and consensus statements were generated based on high-quality evidence. In intermediate-stage HCC, preservation of liver function is as important as achieving a high objective response (OR) because the treatment goal is to prolong overall survival. Superselective conventional TACE (cTACE) is recommended as the first choice of treatment in patients eligible for effective (curative) TACE, whereas in patients who are not eligible, systemic therapy is recommended as the first choice of treatment. TACE is not indicated as the first-line therapy in TACE-unsuitable patients. Another important statement is that TACE should not be continued in patients who develop TACE failure/refractoriness in order to preserve liver function. Targeted therapy is the recommended first-line treatment for TACE-unsuitable patients. Especially, the drug, which can have higher OR rate, is preferred. Immunotherapy, transarterial radioembolization, TACE + targeted therapy or other modalities may be considered alternative options in TACE-unsuitable patients who are not candidates for targeted therapy. Better liver function, such as albumin-bilirubin grade 1, is an important factor for maximizing the therapeutic effect of systemic therapy.
119 citations
••
TL;DR: Extracorporeal membrane oxygenation-assisted PCI for patients with AMI that is complicated by profound CS may improve the 30-day and 1-year survival rates.
119 citations
••
TL;DR: Physicians not only need to be aware of the pharmacodynamic and pharmacokinetic interactions of various important drugs, but also need to update their knowledge.
Abstract: Congenital long QT syndrome (LQTS) is a rare but potentially lethal disease, characterized by prolongation of QT interval, recurrent syncope, and sudden death. In the pregenomic era (1959 -1991), sympathetic imbalance was thought to be responsible for this disease. Since 1991 (postgenomic era), 7 LQTS genes have been discovered and more than 300 mutations have been identified to account for approximately 70% of patients affected. Despite the advancement in molecular genetic knowledge, diagnosis of congen- ital LQTS is still based on electrocardiographic and clinical charac- teristics. Beta-blockers remain the mainstay treatment. For high-risk patients, the implantable cardioverter-defibrillator (ICD) offer an effective therapeutic option to reduce mortality. Gene-based specific therapy is still preliminary. Further studies are required to investi- gate new strategies for targeting the defective genes or mutant channels. For acquired LQTS, it is generally believed that the main issue is the blockade of the slow component of the delayed rectifier K current (IKr). These IKr blockers have a "reverse frequency- dependent" effect on the QTc interval and increase the dispersion in repolarization. In the presence of risk factors such as female gender, slow heart rate, and hypokalemia, these IKr blockers have a high propensity to induce torsades de pointes. For patients with a history of drug-induced LQTS, care must be taken to avoid further exposure to QT-prolonging drugs or conditions. Molecular genetic analysis could be useful to unravel subclinical mutations or polymorphisms. Physicians not only need to be aware of the pharmacodynamic and pharmacokinetic interactions of various important drugs, but also need to update their knowledge.
119 citations
Authors
Showing all 11952 results
Name | H-index | Papers | Citations |
---|---|---|---|
Peng Huang | 95 | 590 | 39098 |
Hui Y. Lan | 86 | 248 | 23383 |
Yau-Huei Wei | 78 | 385 | 22286 |
Chunyu Liu | 76 | 450 | 26738 |
Ching-Yu Cheng | 75 | 541 | 39780 |
Shou-Dong Lee | 75 | 788 | 26066 |
Shih Ann Chen | 73 | 698 | 28441 |
Shuu Jiun Wang | 71 | 502 | 24800 |
Pesus Chou | 65 | 481 | 16907 |
Jong Ling Fuh | 65 | 383 | 19559 |
Shing Jong Lin | 63 | 401 | 13236 |
Charles Y. Chiu | 62 | 236 | 13185 |
Bor-Luen Chiang | 60 | 460 | 13597 |
Tzeng Ji Chen | 60 | 541 | 13644 |
Shih Hwa Chiou | 58 | 262 | 12289 |